2114 completed, 560 recruiting, 556 terminated, 458 unknown. 1785 Phase 2, 1524 Phase 1, 437 Not applicable, 365 Phase 3, 81 Phase 4.
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-08-26 |
| VR-PAT and fNIRS to Identify CNS Biomarkers of Pain VR-PAT - Acute Pain, Pediatric ALL | Not applicable | Not yet recruiting | Nationwide Children's Hospital | 4 | 2027-07-01 | 2026-09-09 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-26 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| 2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy CAR T cell therapy - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-03-01 | 2026-10-05 |
| Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration Non-Interventional Study - Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma | Not yet recruiting | Mayo Clinic | 20 | 2027-02-01 | 2026-04-02 | |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | University of Alberta | 80 | 2027-01-02 | 2026-08-12 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-10-26 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Prevention of Oral Mucositis in Adults in With Hematologic Malignancy Aloe Vera Mouthwash, Standard of Care - Acute Leukemia, Acute Myeloid Leukemia | Not applicable | Not yet recruiting | Wake Forest University Health Sciences | 206 | 2027-01-01 | 2026-10-22 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
Showing 20 of 4341. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (2521) · Leukemia, Lymphocytic, Chronic, B-Cell (2019) · Lymphoma, Non-Hodgkin (961) · Leukemia (945) · Leukemia, Myeloid, Acute (943) · Lymphoma (763) · Lymphoma, Follicular (749) · Lymphoma, Mantle-Cell (721) · Lymphoma, Large B-Cell, Diffuse (684) · Burkitt Lymphoma (660) · Lymphoma, B-Cell, Marginal Zone (641) · Myelodysplastic Syndromes (587) · Hodgkin Disease (563) · Multiple Myeloma (478) · Lymphoma, Large-Cell, Immunoblastic (450)
Hemic and Lymphatic Diseases (4341) · Neoplasms by Histologic Type (4331) · Immunoproliferative Disorders (4325) · Lymphatic Diseases (4323) · Immune System Diseases (4321) · Hematologic Diseases (4307) · Lymphoproliferative Disorders (4276) · Neoplasms (4125) · Leukemia (3396) · Pathological Conditions, Signs and Symptoms (2617) · Pathologic Processes (2562) · Disease Attributes (2470) · Chronic Disease (2309) · Leukemia, B-Cell (1958)
Cyclophosphamide (629) · Rituximab (382) · fludarabine phosphate (300) · Methotrexate (293) · Cytarabine (289) · fludarabine (272) · Vincristine (242) · Dexamethasone (218) · Etoposide (181) · venetoclax (180) · Filgrastim (170) · Peripheral Blood Stem Cell Transplantation (168) · Doxorubicin (151) · Whole-Body Irradiation (144) · Mycophenolic Acid (141)
National Cancer Institute (NCI) (250) · M.D. Anderson Cancer Center (200) · Fred Hutchinson Cancer Center (125) · Children's Oncology Group (77) · St. Jude Children's Research Hospital (74) · City of Hope Medical Center (72) · Memorial Sloan Kettering Cancer Center (72) · Mayo Clinic (51) · Masonic Cancer Center, University of Minnesota (49) · Dana-Farber Cancer Institute (45) · Institute of Hematology & Blood Diseases Hospital, China (42) · Gruppo Italiano Malattie EMatologiche dell'Adulto (41) · Novartis Pharmaceuticals (41) · AbbVie (38) · Gilead Sciences (38)
United States (2676) · China (403) · France (323) · Italy (310) · Canada (293) · Germany (275) · United Kingdom (250) · Spain (234) · Australia (216) · Poland (131) · Belgium (127) · Netherlands (121) · Israel (118) · Denmark (110) · Austria (108)
Brenda Sandmaier (14) · Elias Jabbour (10) · Michael Hallek, MD (10)
PMID 41671463, PMID 34515338, PMID 35622074, PMID 32499241, PMID 34398557, PMID 38620092, PMID 23524640, PMID 33242441, PMID 23065508, PMID 29358183, PMID 31196847, PMID 34048072, PMID 39121442, PMID 26182309, PMID 27209293, PMID 31023700, PMID 34608724, PMID 34865212, PMID 39563886, PMID 40266025, PMID 41592282, PMID 22442346, PMID 24615776, PMID 24615777, PMID 25103870, PMID 28054442, PMID 28751558, PMID 33131249, PMID 35007144, PMID 35422096, PMID 35829925, PMID 36442911, PMID 36858787, PMID 37341189, PMID 37890117, PMID 38446568, PMID 38502198, PMID 40195173, PMID 40396505, PMID 41429239, PMID 41843779, PMID 15812540, PMID 16344317, PMID 19141862, PMID 19144982, PMID 19238148, PMID 19826119, PMID 19949018, PMID 20028764, PMID 20882050
P30CA015704 (59), P30CA033572 (50), U10CA098543 (31), P30CA015083 (28), 2023 (26), P30CA006973 (24), P30CA043703 (24), P30CA016672 (22), P01CA018029 (21), U10CA031946 (21), 2015 (19), 2016 (18), 2025 (18), U10CA032102 (18), U10CA180886 (18)